Literature DB >> 15542967

Sepsis associated with immunosuppressive medications: an evidence-based review.

Juan C Gea-Banacloche1, Steven M Opal, James Jorgensen, Joseph A Carcillo, Kent A Sepkowitz, Catherine Cordonnier.   

Abstract

OBJECTIVE: In 2003, critical care and infectious disease experts representing 11 international organizations developed management guidelines for sepsis associated with immunosuppressive medications that would be of practical use for the bedside clinician, under the auspices of the Surviving Sepsis Campaign, an international effort to increase awareness and improve outcome in severe sepsis.
DESIGN: The process included a modified Delphi method, a consensus conference, several subsequent smaller meetings of subgroups and key individuals, teleconferences, and electronic-based discussion among subgroups and among the entire committee.
METHODS: The modified Delphi methodology used for grading recommendations built on a 2001 publication sponsored by the International Sepsis Forum. We undertook a systematic review of the literature graded along five levels to create recommendation grades from A to E, with A being the highest grade. Pediatric considerations to contrast adult and pediatric management are in the article by Parker et al. on p. S591.
CONCLUSION: Immunosuppressed patients, by definition, are susceptible to a wider spectrum of infectious agents than immunologically normal patients and, thus, require a broader spectrum antimicrobial regimen when they present with sepsis or septic shock. Special expertise managing immunosuppressed patient populations is needed to predict and establish the correct diagnosis and to choose appropriate empiric and specific agents and maximize the likelihood that patients will survive these microbial challenges.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15542967     DOI: 10.1097/01.ccm.0000143020.27340.ff

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  13 in total

1.  17(R)-Resolvin D1 differentially regulates TLR4-mediated responses of primary human macrophages to purified LPS and live E. coli.

Authors:  Christine D Palmer; Christy J Mancuso; Jerrold P Weiss; Charles N Serhan; Eva C Guinan; Ofer Levy
Journal:  J Leukoc Biol       Date:  2011-06-07       Impact factor: 4.962

2.  The novel immunotherapeutic oligodeoxynucleotide IMT504 protects neutropenic animals from fatal Pseudomonas aeruginosa bacteremia and sepsis.

Authors:  Abdullah Chahin; Steven M Opal; Jorge Zorzopulos; David V Jobes; Yazan Migdady; Michelle Yamamoto; Nicholas Parejo; John E Palardy; David L Horn
Journal:  Antimicrob Agents Chemother       Date:  2014-12-15       Impact factor: 5.191

3.  Inpatient Mortality Among Solid Organ Transplant Recipients Hospitalized for Sepsis and Severe Sepsis.

Authors:  John P Donnelly; Jayme E Locke; Paul A MacLennan; Gerald McGwin; Roslyn B Mannon; Monika M Safford; John W Baddley; Paul Muntner; Henry E Wang
Journal:  Clin Infect Dis       Date:  2016-05-23       Impact factor: 9.079

Review 4.  Non-viral infections in children after renal transplantation.

Authors:  Francesca Mencarelli; Stephen D Marks
Journal:  Pediatr Nephrol       Date:  2012-02-09       Impact factor: 3.714

5.  Oral infection control to assist infliximab therapy in a Behçet's disease patient with severe eye inflammation in response to dental treatment: a case report.

Authors:  Chieko Kudo; Hiroshi Wakabayashi; Masayuki Shimoe; Hiroya Kobayashi; Takashi Ito; Toshinori Ohkawa; Arisa Isoshima-Nakamura; Junji Mineshiba; Norie Yoshioka; Kumiko Nawachi; Hiroshi Maeda; Toshihiko Matsuo; Hirofumi Makino; Shogo Takashiba
Journal:  Clin Case Rep       Date:  2014-09-04

Review 6.  Epidemiology and Immune Pathogenesis of Viral Sepsis.

Authors:  Gu-Lung Lin; Joseph P McGinley; Simon B Drysdale; Andrew J Pollard
Journal:  Front Immunol       Date:  2018-09-27       Impact factor: 7.561

7.  [Requirements for hygiene in the medical care of immunocompromised patients. Recommendations from the Committee for Hospital Hygiene and Infection Prevention at the Robert Koch Institute (RKI)].

Authors: 
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2010-04       Impact factor: 1.513

8.  Use of methylene blue for treatment of severe sepsis in an immunosuppressed patient after liver transplantation.

Authors:  Saravanan Ramamoorthy; Shachi Patel; Eric Bradburn; Zakiyah Kadry; Tadahiro Uemura; Piotr K Janicki; Riaz Ali Shah; Dmitri Bezinover
Journal:  Case Rep Transplant       Date:  2013-05-13

9.  Sepsis in AIDS patients: clinical, etiological and inflammatory characteristics.

Authors:  João Manoel Silva; Sigrid De Sousa dos Santos
Journal:  J Int AIDS Soc       Date:  2013-01-30       Impact factor: 5.396

Review 10.  Sterile post-traumatic immunosuppression.

Authors:  Md Nahidul Islam; Benjamin A Bradley; Rhodri Ceredig
Journal:  Clin Transl Immunology       Date:  2016-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.